Consensus LifeMD, Inc.

Equities

LFMD

US53216B1044

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
8.22 ^USD	+9.16%		+3.92%	-0.84%

Jun. 05	KeyBanc Initiates LifeMD at Overweight With $12 Price Target, Cites 'Strong Top & Bottom-Line Growth'	MT
May. 09	Cantor Fitzgerald Adjusts LifeMD's Price Target to $15 From $13, Keeps Overweight Rating	MT

Evolution of the average Target Price on LifeMD, Inc.

Price target over the last 5 years

History of analyst recommendation changes

acf6baacb0562c7a0959.s9r2qRfzdkRBRr6DJoZ1tY9xogOUtarZn450CDPmGf0.27G93WTGBzINFvXIQMw6hL9F5DTc8uuA57YNPQPXK47wu4z-ZpAxDRII9w~22a29449e2e62654ffa95501adc83511

Analyst Recommendations on LifeMD, Inc.

KeyBanc Initiates LifeMD at Overweight With $12 Price Target, Cites 'Strong Top & Bottom-Line Growth'	Jun. 05	MT
Cantor Fitzgerald Adjusts LifeMD's Price Target to $15 From $13, Keeps Overweight Rating	May. 09	MT
BTIG Adjusts LifeMD's Price Target to $14 From $13, Keeps Buy Rating	Apr. 23	MT
Craig-Hallum Adjusts LifeMD's Price Target to $15 From $10, Maintains Buy Rating	Mar. 12	MT
Cantor Fitzgerald Adjusts Price Target on LifeMD to $11 From $9, Maintains Overweight Rating	Mar. 12	MT
B. Riley Securities Lifts LifeMD's PT to $12 From $11 After 'Strong' Q4 2023 Results, Maintains Buy Rating	Mar. 12	MT
HC Wainwright Adjusts LifeMD Price Target to $12 From $10, Maintains Buy Rating	Jan. 11	MT
Cantor Fitzgerald Adjusts LifeMD's Price Target to $9 From $8, Maintains Overweight Rating	Nov. 14	MT
HC Wainwright Adjusts Price Target on LifeMD to $10 From $9, Maintains Buy Rating	Nov. 09	MT
B. Riley Raises LifeMD's Price Target to $11 From $7 After Q3 Topline Beat, Maintains Buy Rating	Nov. 09	MT
Cantor Fitzerald Adjusts LifeMD Price Target to $8 From $7, Maintains Overweight Rating	23-10-02	MT
Cantor Fitzgerald Starts LifeMD at Overweight With $7 Price Target	23-07-21	MT
B. Riley Raises LifeMD's PT to $7 From $3.50 on Increased Conviction for Durable Growth, Enhanced EBITDA; Keeps Buy Rating	23-07-10	MT
HC Wainwright Initiates LifeMD With Buy Rating, $9 Price Target	23-07-03	MT
BTIG Research Adjusts LifeMD Price Target to $7 From $8, Maintains Buy Rating	23-03-23	MT
BTIG Research Adjusts LifeMD Price Target to $7 From $8, Maintains Buy Rating	23-03-23	MT
B. Riley Lowers LifeMD's Price Target to $8 from $16, Notes Slower-than-Anticipated Start in Q1 Impacted by Technology Upgrades, Integrations; Keeps Buy Rating	22-05-16	MT
BTIG Adjusts LifeMD's Price Target to $15 From $30, Reiterates Buy Rating	21-11-11	MT
LIFEMD : BTIG Research Adjusts LifeMD Price Target to $30 From $35, Maintains Buy Rating	21-08-13	MT
LIFEMD : BTIG Adjusts LifeMD's Price Target to $35 From $40, Reiterates Buy Rating	21-07-19	MT
CONVERSION LABS : B. Riley Starts Conversion Labs at Buy With $35 Price Target	21-02-05	MT
CONVERSION LABS : BTIG Starts Conversion Labs at Buy With $15 Price Target	21-01-07	MT